Overview

Acalabrutinib in Combination With Rituximab and R-miniCHOP in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.

Phase:

Phase 3

Details

Lead Sponsor:

Universität des Saarlandes

Collaborators:

AstraZeneca
Saarland Universtity Medical Center, Radiology
University Hospital of Gießen and Marburg, Molecular Pathology
University Hospital of Würzburg, Pathology
University Hospital Regensburg, Nuclear Medicine
University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology (IMISE)

Treatments:

Acalabrutinib